Global TradFi & Macroeconomics

Focus on price action and volatility across stocks, bonds, forex, commodities, and major indices. Analyze macro indicators like interest rates, inflation, employment, and policy expectations to decode global liquidity shifts, risk sentiment, and cross-market correlations.
All
Stocks
Metals
Indices
Forex
Commodities

Tenax Therapeutics Stocks Crash 89% After TNX-103 Phase 3 Trial Failure

Tenax Therapeutics (TENX) stock crashed nearly 89% to a record low in early trading on Monday after the company's experimental drug TNX-103 failed to meet the primary endpoint of a Phase 3 trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (P
LucasBennett·08-10 14:27
Tenax Therapeutics Stocks Crash 89% After TNX-103 Phase 3 Trial Failure

BTC traded in a narrow range over the past hour, up 0.02%: Chain-split risk exacerbated by the diversion of safe-haven funds

From 13:00 to 14:00 UTC on August 10, 2026, BTC fluctuated within a narrow range of 64,847.7–64,905.8 USDT, posting a return of just +0.02% and an amplitude of 0.09%. It is currently trading at approximately $64,662, down 0.86% over the past 24 hours. The combination of low trading volume and a modest decline indicates limited market participation, with the broader market remaining extremely range-bound. Several industry-specific negative factors contributed to BTC’s weak performance. First, the
BTC-0.13%
MARA1.25%
GLDX-0.07%
PAXG0.32%
GateNews·08-10 14:04
BTC traded in a narrow range over the past hour, up 0.02%: Chain-split risk exacerbated by the diversion of safe-haven funds

SpaceX Stock Rebounds to Near $135 IPO Price After Q2 Revenue Beat

SpaceX shares rose on Monday, bringing the stock back around its $135 IPO price after volatile post-IPO trading that saw shares close as low as $108.27 days ago. The rebound followed the rocket maker's first earnings report since its historic Nasdaq debut in June, where it reported
SPCX2.22%
LucasBennett·08-10 13:47
SpaceX Stock Rebounds to Near $135 IPO Price After Q2 Revenue Beat